126 related articles for article (PubMed ID: 18468400)
1. Immunization with a tissue vaccine enhances the effect of irradiation on prostate tumors.
Suckow MA; Wheeler J; Wolter WR; Sailes V; Yan M
In Vivo; 2008; 22(2):171-7. PubMed ID: 18468400
[TBL] [Abstract][Full Text] [Related]
2. Use of an extracellular matrix material as a vaccine carrier and adjuvant.
Suckow MA; Hall P; Wolter W; Sailes V; Hiles MC
Anticancer Res; 2008; 28(5A):2529-34. PubMed ID: 19035274
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of prostate cancer metastasis by administration of a tissue vaccine.
Suckow MA; Wolter WR; Sailes VT
Clin Exp Metastasis; 2008; 25(8):913-8. PubMed ID: 18821060
[TBL] [Abstract][Full Text] [Related]
4. Prevention of human PC-346C prostate cancer growth in mice by a xenogeneic tissue vaccine.
Suckow MA; Rosen ED; Wolter WR; Sailes V; Jeffrey R; Tenniswood M
Cancer Immunol Immunother; 2007 Aug; 56(8):1275-83. PubMed ID: 17242926
[TBL] [Abstract][Full Text] [Related]
5. Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy.
Neeley YC; Arredouani MS; Hollenbeck B; Eng MH; Rubin MA; Sanda MG
Prostate; 2008 May; 68(7):715-27. PubMed ID: 18302222
[TBL] [Abstract][Full Text] [Related]
6. CpG oligonucleotide as an adjuvant for the treatment of prostate cancer.
Lubaroff DM; Karan D
Adv Drug Deliv Rev; 2009 Mar; 61(3):268-74. PubMed ID: 19166887
[TBL] [Abstract][Full Text] [Related]
7. Prevention of de novo prostate cancer by immunization with tumor-derived vaccines.
Suckow MA; Wolter WR; Pollard M
Cancer Immunol Immunother; 2005 Jun; 54(6):571-6. PubMed ID: 15685450
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines.
Vieweg J; Rosenthal FM; Bannerji R; Heston WD; Fair WR; Gansbacher B; Gilboa E
Cancer Res; 1994 Apr; 54(7):1760-5. PubMed ID: 8137291
[TBL] [Abstract][Full Text] [Related]
9. Adenoviral vector-mediated RTVP-1 gene-modified tumor cell-based vaccine suppresses the development of experimental prostate cancer.
Naruishi K; Timme TL; Kusaka N; Fujita T; Yang G; Goltsov A; Satoh T; Ji X; Tian W; Abdelfattah E; Men T; Watanabe M; Tabata K; Thompson TC
Cancer Gene Ther; 2006 Jul; 13(7):658-63. PubMed ID: 16485011
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of murine prostate cancer using whole tumour cells killed ex vivo by cytosine deaminase/5-fluorocytosine suicide-gene therapy.
Pandha HS; Cook D; Greenhalgh R; Dalgleish A
BJU Int; 2005 Jun; 95(9):1336-43. PubMed ID: 15892827
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic vaccination against malignant gliomas based on allorecognition and syngeneic tumor antigens: proof of principle in two strains of rat.
Stathopoulos A; Samuelson C; Milbouw G; Hermanne JP; Schijns VE; Chen TC
Vaccine; 2008 Mar; 26(14):1764-72. PubMed ID: 18336964
[TBL] [Abstract][Full Text] [Related]
12. Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent anti-tumor-preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions.
Mortara L; Frangione V; Castellani P; De Lerma Barbaro A; Accolla RS
Int Immunol; 2009 Jun; 21(6):655-65. PubMed ID: 19395374
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of human prostate cancer xenograft growth by 125I labeled triple-helix forming oligonucleotide directed against androgen receptor.
Zhang Y; Ma Y; Lu HP; Gao JH; Liang CS; Liu CZ; Zou JT; Wang HQ
Chin Med J (Engl); 2008 Nov; 121(22):2284-9. PubMed ID: 19080333
[TBL] [Abstract][Full Text] [Related]
14. Antitumor immunity by a dendritic cell vaccine encoding secondary lymphoid chemokine and tumor lysate on murine prostate cancer.
Lu J; Zhang Q; Liang CM; Xia SJ; Zhong CP; Wang DW
Asian J Androl; 2008 Nov; 10(6):883-9. PubMed ID: 18958352
[TBL] [Abstract][Full Text] [Related]
15. Small intestinal submucosa does not promote PAIII tumor growth in Lobund-Wistar rats.
Hodde JP; Suckow MA; Wolter WR; Hiles MC
J Surg Res; 2004 Aug; 120(2):189-94. PubMed ID: 15234212
[TBL] [Abstract][Full Text] [Related]
16. Effect of a metalloporphyrin antioxidant (MnTE-2-PyP) on the response of a mouse prostate cancer model to radiation.
Makinde AY; Luo-Owen X; Rizvi A; Crapo JD; Pearlstein RD; Slater JM; Gridley DS
Anticancer Res; 2009 Jan; 29(1):107-18. PubMed ID: 19331139
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy of prostate cancer in a murine model using a novel GnRH based vaccine candidate.
Junco JA; Peschke P; Zuna I; Ehemann V; Fuentes F; Bover E; Pimentel E; Basulto R; Reyes O; Calzada L; Castro MD; Arteaga N; López Y; Garay H; Hernández H; Bringas R; Guillén GE
Vaccine; 2007 Dec; 25(50):8460-8. PubMed ID: 18022737
[TBL] [Abstract][Full Text] [Related]
18. Selenite treatment inhibits LAPC-4 tumor growth and prostate-specific antigen secretion in a xenograft model of human prostate cancer.
Bhattacharyya RS; Husbeck B; Feldman D; Knox SJ
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):935-40. PubMed ID: 18760546
[TBL] [Abstract][Full Text] [Related]
19. Effect of different components of laser immunotherapy in treatment of metastatic tumors in rats.
Chen WR; Liu H; Ritchey JW; Bartels KE; Lucroy MD; Nordquist RE
Cancer Res; 2002 Aug; 62(15):4295-9. PubMed ID: 12154032
[TBL] [Abstract][Full Text] [Related]
20. [Effects of anti-gene and antisense therapeutics on human prostate cancer xenograft in nude mice].
Zhang Y; Ma Y; Lu HP; Zhou XF; Xie Y; Gao JH; Liang CS
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(29):2073-6. PubMed ID: 19080439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
